GCG and metabolic dysfunction-associated steatotic liver disease: Understanding these mechanisms will aid in the development of more effective therapeutic strategies that target various aspects of the glucagon signaling pathway, alleviating the hepatic burden in NAFLD patients and improving disease outcomes.